Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomized, Double-blind Controlled Trial of Olanzapine Versus Placebo in Addition to Ondansetron Plus Dexamethasone As Antiemetic Prophylaxis in Patients Receiving Moderately Emetogenic Chemotherapy

NCT06850454 is registered in ClinicalTrials.gov with Mahidol University as lead sponsor.

NCT NCT06850454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06850454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomized, Double-blind Controlled Trial of Olanzapine Versus Placebo in Addition to Ondansetron Plus Dexamethasone As Antiemetic Prophylaxis in Patients Receiving Moderately Emetogenic Chemotherapy
Lead sponsor
Mahidol University
Phase
Phase 3
Overall status
Recruiting
Start date
January 10, 2025
Completion date
January 31, 2026
Enrollment
140 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy induced nausea and vomiting